Steris Plc (STE) - Q3 Fiscal 2026 Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2025 (Q3 of Fiscal Year 2026) and the nine months ended December 31, 2025. Steris Plc is a global provider of infection prevention products and services, operating through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in May 2024 and is reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $1,496.2 | $1,370.6 | $4,347.5 | $3,979.0 |
| Gross Profit | $655.5 | $610.3 | $1,929.4 | $1,761.6 |
| Gross Margin % | 43.8% | 44.5% | 44.4% | 44.3% |
| Income from Operations | $273.2 | $245.3 | $785.0 | $650.5 |
| Net Income (Attributable to Shareholders) | $192.9 | $173.5 | $562.1 | $469.0 |
| Diluted EPS | $1.96 | $1.75 | $5.69 | $4.73 |
| Operating Cash Flow (9M) | $1,006.0 (2025) vs $887.3 (2024) | |||
| Free Cash Flow (9M) | $737.6 (2025) vs $588.1 (2024) | |||
| Total Debt | $1,898.4 | (Balance Sheet: Dec 31, 2025) | ||
| Cash & Equivalents | $423.7 | (Balance Sheet: Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9.2% in Q3 and 9.3% for the nine-month period, driven by higher volume and pricing across all three segments. Organic growth was 9.2% (Q3) and 9.3% (9M).
- Margin Pressure: Q3 gross margin decreased 70 basis points to 43.8% due to unfavorable impacts from tariffs (120 bps), inflation (60 bps), and mix, which offset benefits from pricing and productivity. The nine-month margin remained stable at 44.4%.
- Restructuring: Restructuring expenses dropped significantly to $0.4 million in Q3 (vs. $2.2 million prior year) and $4.4 million for the nine months (vs. $30.7 million prior year), contributing to higher operating income.
- Interest Expense: Interest expense decreased to $14.9 million in Q3 (vs. $19.1 million) and $45.6 million for the nine months (vs. $69.1 million) due to lower debt principal balances following the Dental segment divestiture.
- Segment Performance:
- Healthcare: Revenue +9.0% (Q3); Operating Income +4.5%.
- AST: Revenue +11.0% (Q3); Operating Income +11.6%.
- Life Sciences: Revenue +6.9% (Q3); Operating Income +6.3%.
Guidance, Outlook, and Risks
Management Commentary: Management attributes growth to volume and pricing benefits. The restructuring plan, initiated in May 2024, is expected to improve annual operating income by approximately $25.0 million in fiscal 2026 and beyond. No specific full-year financial guidance was provided in this text.
Capital Allocation:
- Dividends: Declared $0.63 per share in Q3 ($1.83 for the nine months).
- Share Repurchases: Repurchased 0.6 million shares for $150.0 million in the first nine months. $150.0 million remains available under the current program.
- Acquisitions: Completed two tuck-in acquisitions for $23.4 million in the first nine months.
Risks and Contingencies:
- Legal: Entered into settlement agreements regarding ethylene oxide (EO) litigation in Illinois for up to $48.2 million (accrued in fiscal 2025). The company is contesting an IRS Notice of Deficiency regarding a potential $50.0 million tax liability but has not established a reserve.
- Macro: Risks include inflation, tariff costs, currency fluctuations, and potential impacts from the U.S. "One Big Beautiful Bill Act" (OBBBA) on tax policies, though management does not expect a material impact on the effective tax rate for the current period.
Investor Verification Checklist
- Margin Sustainability: Verify if tariff and inflation headwinds are temporary or structural, given the 70 bps gross margin compression in Q3.
- EO Litigation Resolution: Confirm the status of the Illinois EO settlement administration process and potential for additional claims beyond the $48.2 million accrual.
- IRS Dispute: Monitor the outcome of the U.S. Tax Court petitions regarding the $50.0 million deemed dividend inclusion.
- Backlog Trends: Healthcare backlog decreased slightly to $429.0 million (from $434.9 million), while Life Sciences backlog increased to $113.4 million (from $85.1 million); verify shipment timing impacts.
- Debt Maturity: Review the schedule for the remaining $1.9 billion in debt, noting the recent repayment of $125 million in Private Placement Senior Notes.